MedTrace Logo

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

NCT05071937 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2025-06-22

No results posted yet for this study

Summary

This Phase 2, open label, study with safety lead in of oral talazoparib in combination with ZEN003694 given daily in 28-day cycles will enroll patients with recurrent ovarian, fallopian tube or primary peritoneal carcinoma.

Conditions

Interventions

DRUG

ZEN003694

ZEN003694 has shown promising activity in the treatment of solid tumors and hematologic (blood) cancers by reducing the multiplication of cancer cells.

DRUG

Talazoparib

Talazoparib kills cancer cells by inhibiting and trapping the enzyme PARP, which is known to be involved in the development of many types of cancers.

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Zenith Epigenetics

    collaborator INDUSTRY

  • Alexander B Olawaiye, MD

    lead OTHER

Principal Investigators

  • Alexander B Olawaiye, MD · UPMC Hillman Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-21
Primary Completion
2031-12-31
Completion
2033-03-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05071937 on ClinicalTrials.gov